DMG Drug Repurposing Navigator
FDA-approved SSRIs synergize with CDK9 inhibitors to kill diffuse midline glioma cells — meaning drugs that are safe, cheap, brain-penetrant, and already FDA-approved may have immediate translational potential in a childhood brain cancer with no effective treatments.
DMG Drug Repurposing Navigator
FDA-approved SSRIs synergize with CDK9 inhibitors to kill diffuse midline glioma cells — meaning drugs that are safe, cheap, brain-penetrant, and already FDA-approved may have immediate translational potential in a childhood brain cancer with no effective treatments.
Build a patient- and caregiver-facing resource specifically for diffuse midline glioma (DMG, formerly DIPG) that tracks drug repurposing research, highlights FDA-approved drugs with emerging preclinical evidence in DMG, and connects families to clinical trials testing these combinations. The site would explain the science in accessible language — including how SSRIs affect histone dopaminylation and why that matters for CDK9 inhibitor effectiveness — while also providing a structured trial finder.
A researcher-facing layer would maintain a curated database of DMG drug combinations supported by preclinical data, organized by the molecular mechanism (CDK9i+SSRI, ONC201, H3K27M-targeted approaches, etc.). Each entry would link to supporting papers, ongoing trials, and key open questions. This would function as a living synthesis of a rapidly moving field.
DMG is an orphan disease with an enormous unmet need and a highly engaged patient/family advocacy community. A resource that bridges the gap between lab discoveries and patient understanding could directly accelerate trial enrollment and reduce the time between promising preclinical discoveries and patient access. The SSRI repurposing angle is uniquely compelling because these drugs are already available, affordable, and well-tolerated even in children.
Who Is This For?
Families of children with DMG/DIPG, pediatric neuro-oncologists, and clinical researchers working on DMG who need a synthesized view of repurposing opportunities and active trials.
Skills & Tools Needed
- Medical/science writing for patient-facing content
- Web development (content management system + trial finder)
- ClinicalTrials.gov API integration
- Knowledge of pediatric brain cancer and neuropharmacology
- Community engagement and patient advocacy network connections
Feasibility
high — Content-driven web platform with trial database integration is well within reach for a small team; the DMG community is highly motivated and would likely partner on curation and dissemination.
Inspired by: H3 dopaminylation and CaMKII modulate diffuse midline glioma response to CDK9 inhibition
